Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.